However, we found a slower treatment response in CML patients carrying an ASXL1 mutation at diagnosis despite mutation clearance in 11/12 of the affected patients in which follow-up samples were analyzed. This evidence concerns the gene ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive.